JP2019522490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522490A5 JP2019522490A5 JP2019518145A JP2019518145A JP2019522490A5 JP 2019522490 A5 JP2019522490 A5 JP 2019522490A5 JP 2019518145 A JP2019518145 A JP 2019518145A JP 2019518145 A JP2019518145 A JP 2019518145A JP 2019522490 A5 JP2019522490 A5 JP 2019522490A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- specific binding
- binding member
- domain
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 10
- 108090001123 antibodies Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 5
- 102000038129 antigens Human genes 0.000 claims 5
- 108091007172 antigens Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000000987 Immune System Anatomy 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Claims (18)
- リンパ球活性化遺伝子3(LAG-3)と結合する特異的結合要素であって、当該特異的結合要素のCH3ドメインに位置するLAG−3抗原結合部位を含み、前記LAG−3結合部位が、アミノ酸配列WDEPWGED(配列番号1)及びPYDRWVWPDE(配列番号3)を含み、前記アミノ酸配列WDEPWGEDが前記CH3ドメインのABループに位置し、前記アミノ酸配列PYDRWVWPDEが前記CH3ドメインのEFループに位置する、特異的結合要素。
- 前記LAG−3抗原結合部位が、前記CH3ドメインのCDループに以下の配列:
(i)SNGQPENNY(配列番号2、8、及び18);
(ii)SNGQPEDNY(配列番号13);
(iii)SNGYPEIEF(配列番号23);
(iv)SNGIPEWNY(配列番号28);
(v)SNGYAEYNY(配列番号33);
(vi)SNGYKEENY(配列番号38);
(vii)SNGVPELNV(配列番号43);又は
(viii)SNGYQEDNY(配列番号48)
の1つをさらに含む、請求項1に記載の特異的結合要素。 - 前記LAG−3抗原結合部位が、前記CH3ドメインのCDループ中に、配列番号2に示されるアミノ酸配列を含む、請求項2に記載の特異的結合要素。
- 配列番号5、10、15、20、25、30、35、40、45、又は50に示される前記CH3ドメインを含む、請求項1から3のいずれか一項に記載の特異的結合要素。
- 配列番号5に示される前記CH3ドメインを含む、請求項4に記載の特異的結合要素。
- CH2ドメインをさらに含む、請求項1から5のいずれか一項に記載の特異的結合要素。
- 前記CH2ドメインが、配列番号53又は配列番号54に示される配列を有する、請求項6に記載の特異的結合要素。
- 配列番号6、7、11、12、16、17、21、22、26、27、31、32、36、37、41、42、46、47、51、又は52に示される配列を含む、請求項1から7のいずれか一項に記載の特異的結合要素。
- 配列番号6又は7に示される配列を含む、請求項8に記載の特異的結合要素。
- 前記CH2ドメインのN末端に、免疫グロブリンヒンジ領域又はその部分をさらに含む、請求項1から9のいずれか一項に記載の特異的結合要素。
- 前記ヒンジ領域又はその部分が、配列番号57又は配列番号58に示される配列を有する、請求項10に記載の特異的結合要素。
- 当該特異的結合要素が、CDRに基づいた抗原結合部位をさらに含み、抗体分子である、請求項1から11のいずれか一項に記載の特異的結合要素。
- 前記抗体分子のCDRに基づいた抗原結合部位が、免疫系調節物質である分子と結合する、請求項12に記載の抗体分子。
- 請求項1から13のいずれか一項に記載の特異的結合要素又は抗体分子をコードする核酸、又は請求項1から13のいずれか一項に記載の特異的結合要素又は抗体分子をコードする核酸を含むベクター。
- 請求項14に記載の核酸又はベクターを含む、組換え宿主細胞。
- 請求項1から13のいずれか一項に記載の特異的結合要素又は抗体分子を産生する方法であって、
請求項15に記載の組換え宿主細胞を、前記特異的結合要素又は前記抗体分子の産生のための条件下で培養する工程を含み、
任意で、前記特異的結合要素又は前記抗体分子を単離及び/又は精製する工程をさらに含む、
方法。 - 請求項1から13のいずれか一項に記載の前記特異的結合要素又は前記抗体分子及び薬学的に許容される賦形剤を含む、薬学的組成物。
- 患者においてがんを処置するための薬学的組成物であって、請求項12又は13に記載の抗体分子を含む、薬学的組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022051878A JP7394162B2 (ja) | 2016-06-20 | 2022-03-28 | Lag-3結合要素 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352470P | 2016-06-20 | 2016-06-20 | |
US62/352,470 | 2016-06-20 | ||
PCT/EP2017/065052 WO2017220555A1 (en) | 2016-06-20 | 2017-06-20 | Lag -3 binding members |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022051878A Division JP7394162B2 (ja) | 2016-06-20 | 2022-03-28 | Lag-3結合要素 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019522490A JP2019522490A (ja) | 2019-08-15 |
JP2019522490A5 true JP2019522490A5 (ja) | 2020-07-27 |
JP7085708B2 JP7085708B2 (ja) | 2022-06-17 |
Family
ID=59269995
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019518145A Active JP7085708B2 (ja) | 2016-06-20 | 2017-06-20 | Lag-3結合要素 |
JP2022051878A Active JP7394162B2 (ja) | 2016-06-20 | 2022-03-28 | Lag-3結合要素 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022051878A Active JP7394162B2 (ja) | 2016-06-20 | 2022-03-28 | Lag-3結合要素 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11214618B2 (ja) |
EP (1) | EP3472206A1 (ja) |
JP (2) | JP7085708B2 (ja) |
KR (1) | KR20190022632A (ja) |
CN (1) | CN109311993B (ja) |
AU (1) | AU2017281157A1 (ja) |
BR (1) | BR112018076525A2 (ja) |
CA (1) | CA3027302A1 (ja) |
IL (1) | IL263715A (ja) |
MX (1) | MX2018016344A (ja) |
RU (1) | RU2018142573A (ja) |
SG (1) | SG11201811184UA (ja) |
TW (1) | TW201831513A (ja) |
WO (1) | WO2017220555A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2858091T3 (es) | 2016-06-20 | 2021-09-29 | F Star Therapeutics Ltd | Moléculas de unión que se unen a PD-L1 y LAG-3 |
BR112018076525A2 (pt) * | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
CN110023337B (zh) | 2016-10-11 | 2024-01-05 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
HRP20231457T1 (hr) | 2017-05-30 | 2024-05-10 | Bristol-Myers Squibb Company | Liječenje lag-3-pozitivnih tumora |
EP4245375A3 (en) | 2017-05-30 | 2023-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
CN111741976A (zh) | 2017-12-19 | 2020-10-02 | F星贝塔有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
CN112584862A (zh) * | 2018-05-17 | 2021-03-30 | 伊米若梅有限公司 | Ch3结构域表位标签 |
CA3107660A1 (en) | 2018-07-26 | 2020-01-30 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
KR20210080437A (ko) | 2018-10-19 | 2021-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종을 위한 조합 요법 |
EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CN114450028A (zh) | 2019-09-22 | 2022-05-06 | 百时美施贵宝公司 | Lag-3拮抗剂治疗的定量空间剖析 |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
CN115942973A (zh) | 2019-11-08 | 2023-04-07 | 百时美施贵宝公司 | 用于黑色素瘤的lag-3拮抗剂疗法 |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
MX2023002332A (es) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular. |
US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
EP4232019A1 (en) | 2020-10-23 | 2023-08-30 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
PE20240820A1 (es) | 2020-12-28 | 2024-04-18 | Bristol Myers Squibb Co | Composiciones de anticuerpos y metodos de uso de los mismos |
BR112023019847A2 (pt) | 2021-03-29 | 2023-11-07 | Juno Therapeutics Inc | Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car |
WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
CN114807054B (zh) * | 2022-06-24 | 2022-09-13 | 北京索莱宝科技有限公司 | 小鼠抗人IgG单抗杂交瘤细胞株、抗体、抗体组合物及试剂盒 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2245404C3 (de) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben |
JPS531908B2 (ja) | 1973-11-12 | 1978-01-23 | ||
JPS5746634B2 (ja) | 1974-05-10 | 1982-10-04 | ||
JPS5146628A (ja) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | Teikoirisupaakupuragu |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE19818214A1 (de) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Zündkerze für eine Brennkraftmaschine |
JP4578025B2 (ja) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | スパークプラグ |
PT2028193E (pt) | 2005-01-05 | 2012-06-15 | Star Biotech Forschung Entw Gmbh | Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
JP5276742B1 (ja) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | 点火プラグ |
CA2902831C (en) | 2013-03-15 | 2023-04-25 | Glaxosmithkline Intellectual Property Development Limited | Anti-lag-3 binding proteins |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
JP5902757B2 (ja) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | スパークプラグ |
WO2015198312A1 (en) * | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JP6665160B2 (ja) | 2014-08-10 | 2020-03-13 | フェデラル−モーグル・イグニション・リミテッド・ライアビリティ・カンパニーFederal−Mogul Ignition Llc | 改良されたシールを有するスパークプラグ |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
RU2017142008A (ru) | 2015-05-21 | 2019-06-24 | Эллигейтор Биосайенс Аб | Новые полипептиды |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
JP6025921B1 (ja) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | スパークプラグ |
US10501510B2 (en) | 2015-07-15 | 2019-12-10 | Pieris Pharmaceuticals Gmbh | Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof |
AR105444A1 (es) | 2015-07-22 | 2017-10-04 | Sorrento Therapeutics Inc | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) |
CA2994631A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
CA3132021C (en) | 2015-11-18 | 2024-03-12 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
US20190330336A1 (en) | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
SG11201805532XA (en) | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins |
DK3445788T3 (en) | 2016-04-22 | 2022-04-11 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
ES2858091T3 (es) | 2016-06-20 | 2021-09-29 | F Star Therapeutics Ltd | Moléculas de unión que se unen a PD-L1 y LAG-3 |
BR112018076525A2 (pt) | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
GB201612520D0 (en) * | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
JP2019528251A (ja) | 2016-07-20 | 2019-10-10 | エスティーキューブ,インコーポレイテッド | グリコシル化pd−l1に結合する抗体の組合せを使用するがんの処置および治療の方法 |
EA201990578A1 (ru) | 2016-09-23 | 2019-10-31 | Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой | |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
AU2018309339A1 (en) | 2017-08-04 | 2020-02-20 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
CN111741976A (zh) | 2017-12-19 | 2020-10-02 | F星贝塔有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
-
2017
- 2017-06-20 BR BR112018076525-2A patent/BR112018076525A2/pt not_active Application Discontinuation
- 2017-06-20 RU RU2018142573A patent/RU2018142573A/ru not_active Application Discontinuation
- 2017-06-20 EP EP17734668.1A patent/EP3472206A1/en active Pending
- 2017-06-20 SG SG11201811184UA patent/SG11201811184UA/en unknown
- 2017-06-20 CN CN201780038556.1A patent/CN109311993B/zh active Active
- 2017-06-20 US US16/311,596 patent/US11214618B2/en active Active
- 2017-06-20 TW TW106120621A patent/TW201831513A/zh unknown
- 2017-06-20 CA CA3027302A patent/CA3027302A1/en active Pending
- 2017-06-20 JP JP2019518145A patent/JP7085708B2/ja active Active
- 2017-06-20 AU AU2017281157A patent/AU2017281157A1/en active Pending
- 2017-06-20 WO PCT/EP2017/065052 patent/WO2017220555A1/en unknown
- 2017-06-20 KR KR1020197001120A patent/KR20190022632A/ko unknown
- 2017-06-20 MX MX2018016344A patent/MX2018016344A/es unknown
-
2018
- 2018-12-16 IL IL263715A patent/IL263715A/en unknown
-
2021
- 2021-11-23 US US17/534,315 patent/US20220185890A1/en active Pending
-
2022
- 2022-03-28 JP JP2022051878A patent/JP7394162B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019522490A5 (ja) | ||
JP2019526273A5 (ja) | ||
JP2020023523A5 (ja) | ||
JP2017160222A5 (ja) | ||
JP2019506841A5 (ja) | ||
JP2016053091A5 (ja) | ||
JP2018512856A5 (ja) | ||
FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
JP2010511388A5 (ja) | ||
JP2018512145A5 (ja) | ||
JP2019536430A5 (ja) | ||
JP2017008046A5 (ja) | ||
JP2012518425A5 (ja) | ||
JP2020500523A5 (ja) | ||
JP2020515518A5 (ja) | ||
JP2020506898A5 (ja) | ||
JP2013537416A5 (ja) | ||
JP2014519830A5 (ja) | ||
RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
JP2010506596A5 (ja) | ||
JP2013529070A5 (ja) | ||
JP2012500006A5 (ja) | ||
JP2015509097A5 (ja) | ||
JP2011521662A5 (ja) | ||
JP2010531140A5 (ja) |